KENALOG-80 (triamcinolone acetonide) by Bristol Myers Squibb is corticosteroid hormone receptor agonists [moa]. First approved in 1965.
Drug data last refreshed Yesterday
KENALOG-80 is a corticosteroid injection containing triamcinolone acetonide that works by binding to corticosteroid hormone receptors to suppress inflammation. It is indicated for 21 conditions spanning ophthalmology (diabetic macular edema, uveitis, age-related macular degeneration), dermatology (atopic dermatitis, psoriasis, contact dermatitis), rheumatology (osteoarthritis, shoulder adhesive capsulitis), and ENT (otitis media with effusion, allergic rhinitis). The drug has been a cornerstone injectable corticosteroid since FDA approval in 1965.
Declining revenue trajectory as patent expiration approaches signals team contraction and shift toward generic defense or lifecycle extension strategies.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Worked on KENALOG-80 at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on KENALOG-80 offers stable but limited career growth; the product is in managed decline with minimal new job creation and modest commercial activity ($10K Part D spending). Career mobility is best pursued by leveraging injectable formulation expertise or moving to higher-growth pipeline assets within Bristol Myers Squibb.